









Markets
/
Stocks
/
nasdaq-cnta
/

Centessa Pharmaceuticals PLC

CNTA

22.970USD

+1.120+5.13%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

3.08BMarket Cap

LossP/E TTM



Centessa Pharmaceuticals PLC

22.970

+1.120+5.13%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

8 / 506

Overall Ranking

64 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

33.000

Target Price

+51.03%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.

Undervalued

The company’s latest PE is -12.41, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 133.71M shares, decreasing 7.57% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 5.91M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 8.37, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.37

Change



Financials

6.54

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.53

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.44

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -11.80, which is -39.48% below the recent high of -7.14 and 29.49% above the recent low of -8.32.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 8/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.53, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Centessa Pharmaceuticals PLC is 33.00, with a high of 40.00 and a low of 27.00.

Score

Industry at a Glance

Previous score

8.53

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Buy

Current Rating

33.000

Target Price

+51.03%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Centessa Pharmaceuticals PLC

CNTA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 9.51, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 25.06 and the support level at 16.83, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.51

Change

0.24

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.828

Buy

RSI(14)

71.960

Buy

STOCH(KDJ)(9,3,3)

88.695

Overbought

ATR(14)

1.400

High Vlolatility

CCI(14)

78.369

Neutral

Williams %R

3.281

Overbought

TRIX(12,20)

1.209

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

21.996

Buy

MA10

20.997

Buy

MA20

18.863

Buy

MA50

17.340

Buy

MA100

15.132

Buy

MA200

15.474

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 100.08%, representing a quarter-over-quarter decrease of 1.52%. The largest institutional shareholder is PRFDX, holding a total of 5.91M shares, representing 4.41% of shares outstanding, with 8.95% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Medicxi Ventures (UK) LLP

19.96M

Index Ventures SA

9.96M

General Atlantic LLC

9.68M

Adage Capital Management, L.P.

6.95M

+35.85%

Janus Henderson Investors

5.92M

+20.63%

T. Rowe Price Associates, Inc.

Star Investors

5.34M

-0.41%

Avoro Capital Advisors LLC

4.05M

Farallon Capital Management, L.L.C.

4.33M

+23.88%

First Light Asset Management, LLC

4.87M

-16.04%

VV Manager LLC

3.93M

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.92, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.